Bitter Pill to Swallow: China’S Flagrant Trade in Leopard Bone Products

Total Page:16

File Type:pdf, Size:1020Kb

Bitter Pill to Swallow: China’S Flagrant Trade in Leopard Bone Products Wildlife A Bitter Pill to Swallow: China’s flagrant trade in leopard bone products April 2020 Wildlife ©EIAimage We would like to thank ABOUT EIA EIA UK 62-63 Upper Street, Ximporae.EIA would Utlike aut to fugitisthank restithe ut atia We investigate and campaign against London N1 0NY UK nobitfollowing ium foralici their bla conesupport: consequam Network environmental crime and abuse. T: +44 (0) 20 7354 7960 cusfor Social aci oditaquates Change, Ernest dolorem Kleinwort volla Our undercover investigations E: [email protected] vendam,Charitable consequo Trust and molor The sinRufford net expose transnational wildlife crime, eia-international.org fugitatur,Foundation. qui int que nihic tem with a focus on elephants and asped quei oditaquates dolorem tigers, and forest crimes such as volla vendam, conseqci oditaquates EIA US illegal logging and deforestation for dolorem volla vendam, consequo PO Box 53343 cash crops like palm oil. We work to molor sin net fugitatur, qui int que Washington DC 20009 USA safeguard global marine ecosystems nihic tem asped quei oditaquates T: +1 202 483 6621 by addressing the threats posed dolorem volla vendam, consuo molor E: [email protected] by plastic pollution, bycatch sin net fugitatur, qui int que nihic eia-global.org and commercial exploitation of tem asped que n nes ape verrovid whales, dolphins and porpoises. maximolorera doles magni tet ea Environmental Investigation Agency Finally, we reduce the impact of voluptas enis as de evel ipsam (UK) Ltd. Company Number: 7752350 climate change by campaigning dolendit, voluptam endusci psunto VAT Number: 440569842. Registered to eliminate powerful refrigerant quibusandit, sitaque enture inEnvironmental England and Investigation Wales Agency UK greenhouse gases, exposing related UK Charity Number: 1182208 illicit trade and improving energy Company Number: 07752350 efficiency in the cooling sector. Registered in England and Wales 2 Environmental Investigation Agency ©EIAimage CONTENTS Above: Leopards have been lost Introduction 4 from 85 per cent of their Asian range with poaching for trade in Background 6 their parts a primary threat Methodology 8 Legitimising consumption: how Government policy permits leopard bone trade 9 Connecting the dots: leopard bone products and Government permits 10 The tip of the iceberg? Permits to trade in protected wildlife issued since 2017 15 Potential for contributing to illegal international trade 16 CITES Parties urge closure of domestic markets for Asian big cats 17 Recommendations 18 Appendix I 19 Appendix II 22 References 23 BITTER PILL TO SWALLOW 3 Introduction Asia’s leopards (Panthera pardus) are in danger of quietly slipping into extinction, with illegal killing to meet demand for their body parts a key driver of their rapid decline. Yet authorities in China – the main source of demand for leopard parts – continue to allow legal commercial trade in traditional medicine products containing leopard bone, which are apparently exempt from wildlife trade bans adopted in the wake of coronavirus COVID-19. In this report, EIA names 24 Chinese companies which appear to be producing and selling products listing leopard bone as an ingredient. It is a measure of the severity of the While decisions adopted by the National current biodiversity crisis that the People’s Congress Standing Committee in leopard, that most adaptable of big cats, February 2020 in the wake of the COVID-19 has disappeared from approximately 85 outbreak have restricted trade in wildlife per cent of its Asian range.1 The figures as food, trade for other purposes such for several Asian subspecies are even as traditional medicine and ornamental more stark: Indochinese leopards are now items is still permitted, including for absent from 94 per cent of their historical protected species. range, extinct or functionally extinct in Laos, Vietnam and Singapore, and almost As China’s own leopard population has extinct in Cambodia and China.2 In China been pushed to near extinction, leopards as a whole, the total population of leopards elsewhere in Asia have been targeted across the country was estimated in 2015 for their body parts. Of a minimum 5,332 to be fewer than 450 individuals.3 Asian leopards that have been seized from illegal trade since 20004, 4,151 were 5 A major factor in the leopard’s continuing seized in India – approximately five-and- ©EIAimage decline throughout Asia is illegal killing a-half times the number of tigers seized for trade in their body parts. Demand in the country during the same period. for their bones, primarily from Chinese These figures comprise seizures of whole ©EIAimage consumers, is one of the drivers of this leopards, as represented by whole skins, trade. Leopard bone is consumed in carcasses, taxidermy specimens or live similar ways to tiger bone, steeped in rice animals; seizures of bone or skeletons are wine to produce health tonics and used in omitted to avoid possible double counting. the production of traditional medicines. As much illegal trade goes undetected or unreported, the true number of leopards in Leopard bone has a long history as an trade is likely far higher. ingredient in traditional Chinese medicine (TCM) and, in addition since a 1993 State Moreover, the number of leopard skins Council Notification (repealed in 2018) seized far exceeds the number of animals banning use of tiger bone and rhino horn represented by seizures of bone. For in medicines, leopard bone has been example, between 2014-18, at least 516 widely used in formulations similar to leopard skins were seized in Asia.6 Based those which would traditionally have on NGO and media reports, EIA was able contained tiger bone. Based on testimony to quantify the seizure of only 250.9kg from individuals engaged in illegal of leopard bone in Asia during the same trade, consumers in China also illegally period – equivalent to the bones of purchase leopard bone that has been sold approximately 32 individual leopards.7 to them as tiger. While this figure is a minimum (with, for example, additional media reports of 4 Environmental Investigation Agency seizure incidents indicating leopard bone Despite the long-standing international was seized without stating a weight), trade ban and a domestic ban on hunting this indicates that reported quantities the few wild leopards remaining in China of leopard bone alone seized from illegal – and thus a lack of any replenishable trade are not an adequate indicator of the legal source – Chinese authorities scale of trafficking. continue to permit large-scale commercial trade in leopard bone products. Snow leopards and clouded leopards – both listed as Vulnerable in the IUCN The existence of a parallel legal market in Red List – are also seriously threatened leopard bone serves to remove the stigma by trade in their body parts. A minimum of consumption and to legitimise use, of 301 snow leopards and 117 clouded while also complicating law enforcement leopards have been seized from illegal efforts. Moreover, there is a total lack of trade since 2000,8 although other transparency from Government agencies estimates of the scale of snow leopard regarding quantities and provenance trade9 and the visibility of clouded of leopard bone in stockpiles. This, set leopards in markets in South-East Asia10 against a backdrop of rampant poaching suggest the true scale of killing for their and trafficking of leopards across Asia body parts is far greater. The term used for with comparatively little leopard bone ‘leopard bone’ in TCM (豹骨 / bao [leopard] being seized from trade, raises the gu [bone]) is ambiguous, as the generic serious possibility that some of the character for leopard – 豹 (bao) – could bone in China’s legal trade is derived be used to refer to leopard, snow leopard, from animals illegally killed outside clouded leopard or even other species China and smuggled into the country in such as jaguar (which translates literally contravention of CITES. as “American leopard”). The TCM term “bao gu” is sometimes translated into Latin as While the majority of TCM practitioners “Os pardi” on product labelling, this being do not use the body parts of threatened a non-scientific term used by the industry wildlife such as leopards, the actions of which has no taxonomic meaning. the companies detailed in this report, as well as the decision-makers who have In recognition of the threat posed to continued to permit the use of leopard these species by commercial trade, the bone, are serving to both exacerbate leopard, snow leopard and clouded leopard threats to Asia’s imperilled big cats and were included on the very first version tarnish the image of traditional Chinese of Appendix I of the Convention on medicine as a whole. International Trade in Endangered Species Top left to right: Snow leopard and clouded leopard. of Wild Fauna and Flora (CITES) when the Both species are threatened by trade in their body parts. Convention was adopted in 1975, banning The ambiguous term for leopard bone “Os pardi” used in traditional Chinese medicine is applied to the bones of international trade in the species or their leopards, snow leopards or clouded leopards parts and derivatives for commercial purposes. Left: Leopard skulls and bones offered illegally for sale in China BITTER PILL TO SWALLOW 5 Background The use of leopard bone in packaged TCM products in China has been reported During the course of research on Down since at least 1994,11 while in 2007 China to the Bone, EIA identified at least 31 first reported to CITES that Government manufacturers which were advertising regulations issued in March 2006 stated a total of 36 products on their websites, that “only existing stock of leopard for which the ingredients list explicitly bones could be used” by pharmaceutical included “leopard bone” [bao gu]. Revisiting manufacturers.12 Quantities of leopard this research in 2019, several of these bone held in such stockpiles and the websites appeared to have gone offline.
Recommended publications
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2017-017557 on 25 September 2017. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay- per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 30, 2021 by guest. Protected copyright. BMJ Open: first published as 10.1136/bmjopen-2017-017557 on 25 September 2017. Downloaded from BMJ Open Vitamin D status in tuberculosis patients with diabetes, pre- diabetes, and normal blood glucose in China ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2017-017557 Article Type: Research Date Submitted by the Author: 04-May-2017 Complete List of Authors: Zhao, Xin; Beijing Hospital,
    [Show full text]
  • 2019 International Religious Freedom Report
    CHINA (INCLUDES TIBET, XINJIANG, HONG KONG, AND MACAU) 2019 INTERNATIONAL RELIGIOUS FREEDOM REPORT Executive Summary Reports on Hong Kong, Macau, Tibet, and Xinjiang are appended at the end of this report. The constitution, which cites the leadership of the Chinese Communist Party and the guidance of Marxism-Leninism and Mao Zedong Thought, states that citizens have freedom of religious belief but limits protections for religious practice to “normal religious activities” and does not define “normal.” Despite Chairman Xi Jinping’s decree that all members of the Chinese Communist Party (CCP) must be “unyielding Marxist atheists,” the government continued to exercise control over religion and restrict the activities and personal freedom of religious adherents that it perceived as threatening state or CCP interests, according to religious groups, nongovernmental organizations (NGOs), and international media reports. The government recognizes five official religions – Buddhism, Taoism, Islam, Protestantism, and Catholicism. Only religious groups belonging to the five state- sanctioned “patriotic religious associations” representing these religions are permitted to register with the government and officially permitted to hold worship services. There continued to be reports of deaths in custody and that the government tortured, physically abused, arrested, detained, sentenced to prison, subjected to forced indoctrination in CCP ideology, or harassed adherents of both registered and unregistered religious groups for activities related to their religious beliefs and practices. There were several reports of individuals committing suicide in detention, or, according to sources, as a result of being threatened and surveilled. In December Pastor Wang Yi was tried in secret and sentenced to nine years in prison by a court in Chengdu, Sichuan Province, in connection to his peaceful advocacy for religious freedom.
    [Show full text]
  • 上海医药企业社会责任报告 SHANGHAI PHARMA CORPORATE SOCIAL RESPONSIBILITY REPORT Definitions
    2018 上海医药企业社会责任报告 SHANGHAI PHARMA CORPORATE SOCIAL RESPONSIBILITY REPORT Definitions In this report, unless the context otherwise requires, the following terms shall have the following meanings: "Shanghai Pharmaceutical Group", "Shanghai Shanghai Pharmaceuticals Holding Co., Ltd. Pharmaceuticals Holding", "Shanghai Pharmaceuticals", "the Company" or "We" Shanghai Pharma Shanghai Pharma Co., Ltd. SPH Keyuan SPH Keyuan Xinhai Pharmaceutical Co., Ltd. SPH Sine Shanghai SPH Sine Pharmaceutical Laboratories Co., Ltd. SPH No. 1 Biochemical and Pharmaceutical Shanghai SPH No. 1 Biochemical and Pharmaceutical Co., Ltd. SPH Traditional Chinese Medicine Shanghai Traditional Chinese Medicine Co., Ltd. SPH Changzhou Pharmaceutical SPH Changzhou Pharmaceutical Co., Ltd. SPH New Asiatic Shanghai SPH New Asiatic Pharmaceutical Co., Ltd. SPH Zhongxi Sunve Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd. SPH Sales Shanghai Pharmaceutical Group Pharma Sales Co., Ltd. SPH Techpool Guangdong Techpool Bio-pharma Co., Ltd. Chiatai Qingchunbao Pharmaceutical Chiatai Qingchunbao Pharmaceutical Co., Ltd. SPH Growful SPH Qingdao Growful Pharmaceutical Co., Ltd. SPH Research Institute Central Research Institute of Shanghai Pharmaceuticals Holding Co., Ltd. Vitaco Vitaco Health (NZ) Limited SPH Herbapex Liaoning SPH Herbapex Pharmaceutical (Group) Co., Ltd. Huqingyutang Pharmaceutical Hangzhou Huqingyutang Pharmaceutical Co., Ltd. SPH Zhonghua Shanghai Zhonghua Pharmaceutical Co., Ltd. SPH Xiamen Traditional Chinese Medicine Xiamen Traditional Chinese Medicine Co.,
    [Show full text]
  • Industry Overview
    THIS DOCUMENT IS IN DRAFT FORM. THE INFORMATION CONTAINED HEREIN IS INCOMPLETE AND IS SUBJECT TO CHANGE. THIS DOCUMENT MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT. INDUSTRY OVERVIEW We engaged CIC for preparing the CIC Report, an independent industry report in respect of the [REDACTED]. Except as otherwise noted, all of the data and forecasts contained in this section have been derived from the CIC Report. We believe that the sources of the information in this section and other sections of this document are appropriate sources for such information, and we have taken reasonable care in extracting and reproducing such information. We have no reason to believe that such information is false or that any fact has been omitted that would render such information misleading. The information from official and non-official sources in this section has been independently verified by CIC, but not by us, the Joint Sponsors, the [REDACTED], the [REDACTED], the [REDACTED], any of the [REDACTED], any of their respective directors and advisers, or any other persons or parties involved in the [REDACTED]. Our Directors confirm that, after making reasonable enquiries, there is no adverse change in the market information since the date of the CIC Report that would qualify, contradict or have a material impact on the information in this Section. OVERVIEW OF HEALTHCARE INDUSTRY IN CHINA The healthcare industry is an important part of China’s national economy. China’s healthcare expenditure is significant and has been growing steadily, from RMB4,097.5 billion in 2015 to RMB7,325.3 billion in 2020, at a CAGR of 12.3%.
    [Show full text]
  • Geographic Variations and Temporal Trends in Cesarean Delivery Rates in China, 2008-2014
    Supplementary Online Content Li H-T, Luo S, Trasande L, et al. Geographic variations and temporal trends in cesarean delivery rates in China, 2008-2014. JAMA. doi:10.1001/jama.2016.18663 eTable 1. Cesarean delivery rate in 2010 for the 94 counties that participated in the China’s National Health Service Survey eTable 2. Local cesarean rates for hospitals that participated in the 2008 WHO survey eTable 3. Cesarean delivery rate in 31 provinces of mainland China, 2008-2014 eTable 4. Cesarean delivery rates in 17 supercities, 2008-2014 eTable 5. Hypothetical cesarean rates in 31 provinces of total population during 2008-2014, assuming that non-resident women have the same delivery pattern as resident women eTable 6. Hypothetical cesarean rates in 31 provinces of total population during 2008-2014, assuming that non-resident women have a one-third lower cesarean rate than resident women eFigure. Funnel plots for county cesarean rates, 2008 and 2014 eReferences This supplementary material has been provided by the authors to give readers additional information about their work. © 2017 American Medical Association. All rights reserved. Downloaded From: https://edhub.ama-assn.org/ on 09/24/2021 eTable 1. Cesarean delivery rate in 2010 for the 94 counties that participated in the China’s National Health Service Survey County name Total live births Cesarean births in County-level cesarean in NHSS data NHSS data rate in the NMCHS data (%)* Dongcheng district 4155 2338 56.3 Miyun county 2691 1518 56.4 Hebei district 3560 2549 71.6 Ji county 9464 5863
    [Show full text]
  • Research Guide to West China Medical Missions (1850-1950)
    Research Guide to West China Medical Missions (1850-1950) 40 Oak Street | Toronto, ON | M5A 2C6 Tel: 416-231-7680 ext. 1101 | Email: [email protected] Last Update: August 01, 2019 TABLE OF CONTENTS Table of Contents INTRODUCTION ................................................................................................................................. 3 ADMINISTRATIVE HISTORY OF WEST CHINA MEDICAL MISSIONS ............................................ 5 THE RECORDS .................................................................................................................................. 8 FONDS 502: UNITED CHURCH OF CANADA BOARD OF OVERSEAS MISSIONS FONDS. -- .... 9 FONDS 503: UNITED CHURCH OF CANADA BOARD OF WORLD MISSION FONDS. -- ......... 160 FONDS 505: UNITED CHURCH OF CANADA WOMAN'S MISSIONARY SOCIETY FONDS. -- . 164 FONDS 500: UNITED CHURCH OF CANADA GENERAL COUNCIL FONDS-- 1925-present. ... 190 FONDS 14: METHODIST CHURCH (CANADA) MISSIONARY SOCIETY FONDS. -- [ca. .......... 196 FONDS 15: METHODIST CHURCH (CANADA) WOMAN'S MISSIONARY SOCIETY FONDS. - 215 PERSONAL PAPERS ..................................................................................................................... 217 FONDS 3133: CECIL MAGEE HOFFMAN FONDS. -- 1908-1979. -- 7 cm of textual records; ..... 217 FONDS 3184: ERNEST BLACK STRUTHERS FONDS. -- 1912-1973. -- 87 cm of textual .......... 217 FONDS 3190: CHARLES W. SERVICE FONDS. -- 1930. -- 1 cm of textual records .................... 223 FONDS 3200: WILLIAM JOHN SHERIDAN FONDS. -- 1912-1935.
    [Show full text]
  • Plurality in Qing Imperial Medicine: Examining Institutional Formations
    Asia Pacific Perspectives ∙ Fall/Winter 2013–14 Plurality in Qing Imperial Medicine: Examining Institutional Formations Beyond the Imperial Medical Bureau Sare Aricanli, Princeton University Abstract This article illustrates the value of using the lens of institutional history to study imperial medicine. Identifying and incorporating a range of organizations and posts into the narrative of imperial medicine in eighteenth-century China shows the breadth of medical activity during this time. The most familiar institution of imperial medicine is the Imperial Medical Bureau, and this study argues that we can greatly benefit from including the history of other formations such as the Imperial Pharmacy and the Ministry of Imperial Stables, Herds, and Carriages. Such an outlook reveals the overlapping spheres of institutions, practitioners, and medicinals between human and equine medicine, implies that ethnicity may have been a factor in the organization of medicine, and points to a wider range of medical practitioners and patients within the imperial realm. Furthermore, multiplicity did not only exist among institutions and practitioners, but also on the linguistic level, as evidenced by the divergence in the meaning of some Manchu and Chinese terminology. Finally, these pluralities suggest that an understanding of imperial medicine as being limited to the Imperial Medical Bureau greatly underestimates the diversity of institutions, posts, ethnicities, and languages within the eighteenth-century Chinese imperial medical world. Keywords: imperial medicine, Imperial Medical Bureau, Imperial Pharmacy, equine care Introduction The history of Chinese medicine has benefited greatly from narratives that rest http://www.usfca.edu/pacificrim/perspectives/ on the textual tradition. Chinese medicine is, however, reflected quite differently through the lenses of textual and institutional history.
    [Show full text]
  • Comparison of Traditional Botano-Therapeutics Between Far-Eastern Countries and Greece
    UNIVERSITY OF IOANNINA SCHOOL OF MEDICINE FACULTY OF HEALTH SCIENCES SECTOR OF CLINICAL AND BASIC FUNCTIONAL SCIENCES DEPARTMENT OF PHARMACOLOGY SECTOR OF SOCIAL MEDICINE AND MENTAL HEALTH HISTORY OF MEDICINE Comparison of Traditional Botano-therapeutics between Far-Eastern Countries and Greece Jayoung Che Dissertation Prepared for the Degree of DOCTOR OF MEDICINE IOANNINA 2016 UNIVERSITY OF IOANNINA SCHOOL OF MEDICINE FACULTY OF HEALTH SCIENCES SECTOR OF CLINICAL AND BASIC FUNCTIONAL SCIENCES DEPARTMENT OF PHARMACOLOGY SECTOR OF SOCIAL MEDICINE AND MENTAL HEALTH HISTORY OF MEDICINE Comparison of Traditional Botano-therapeutics between Far-Eastern Countries and Greece Jayoung Che Dissertation Prepared for the Degree of DOCTOR OF MEDICINE IOANNINA 2016 ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ ΤΜΗΜΑ ΙΑΤΡΙΚΗΣ ΛΕΙΤΟΥΡΓΙΚΟΣ - ÊËÉÍÉÊÏÅÑÃÁÓÔÇÑÉÁÊÏÓ ÔÏÌÅÁÓ ΕΡΓΑΣΤΗΡΙΟ ΦΑΡΜΑΚΟΛΟΓΙΑΣ ΤΟΜΕΑΣ ΚΟΙΝΩΝΙΚΗΣ ΙΑΤΡΙΚΗΣ ΚΑΙ ΨΥΧΙΚΗΣ ΥΓΕΙΑΣ ΙΣΤΟΡΙΑ ΤΗΣ ΙΑΤΡΙΚΗΣ Σύγκριση της παραδοσιακής βοτανοθεραπευτικής μεταξύ των χωρών της Άπω Ανατολής και της Ελλάδας Jayoung Che ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ ΙΩΑΝΝΙΝΑ 2016 E "'-&$ $. &',-&'. &-&!. 45 , )) -&'. ,/ *4&$),/ 2***2**/4,$(7*&4,,02*"*2)7*,//""-#$%&%'%()-%-,(,() 4-"-,.(-*,)&'',06-2$,/ -&',6)),./F# Contents I. Introduction ……………. ………………………………………….. 11 II. Developments of botanical pharmacy in China and Greece ………… 16 A. Developments of Chinese therapeutic botany ……………………… 16 B. Greek Tradition of botanical medicine ……………………………. 28 III. Medicinal philosophy in Eastern Countries and Greece
    [Show full text]
  • Pdf, 512.26 Kb
    Review Article A Brief Introduction of Clinical Chinese Pharmacy Education, Training and Practice in China Zhijian Lin1, Yue Li2, Bing Zhang1,* 1Department of Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, CHINA. 2Department of Health Policy & Management, School of Public Health, University of Minnesota, Minneapolis, MN, US. ABSTRACT In China, there are two types of pharmacists who work on either Western Medicine (WM) or Traditional Chinese Medicine (TCM). Both are responsible for the provision of pharmaceutical care with safe, effective, efficient and accountable medications for patients. Although Traditional Chinese Pharmacy is not a new subject, it faces a new medical environment and requires a transition. In recent years, Traditional Chinese Pharmacy is emerging as an independent discipline, largely due to global acceptance of TCM. With the development of clinical pharmacy and the increase of patients in need of healthcare services, the role of Chinese pharmacists is requiring an imperative reform. Mechanical tasks such as medication dispension are decreasing in hospital and community pharmacies. This change calls for a new model of traditional Chinese pharmacy education to promote the pharmacists’ capacity for advanced direct patient care. Since the late 1990s, some universities and colleges of TCM in China started to offer education and training programs of clinical Chinese pharmacy on various levels. Traditional Chinese Pharmacist education applies training models that closely mirror those of western pharmacists’. Presently, the emphasis of clinical Chinese Pharmacy is beginning to shift to pharmaceutical care practice. With this change, there is an increasing demand for developing clinical skills for clinical Chinese pharmacists, through degree education and non-degree training.
    [Show full text]
  • China's Healthcare System Uncovered
    China’s Healthcare System Uncovered Theme Focus: Online Medicine and Potential Beneficiaries of the COVID-19 Virus Pandemic Q1 2020 KURE Quarterly Earnings Report [email protected] +1 (212) 933 0393 [email protected] +1 (212) 933 0393 Table of Contents KURE Standard Performance 3 China's Healthcare System Uncovered 4 Key Points on China Healthcare Sector 5 China Healthcare Sector Key Charts 6-7 Q1 2020 Performance Review 8 Online Medicine and Beneficiaries of the COVID-19 9-12 Virus Pandemic Overview 12-17 Top 10 KURE Holdings: Quarterly Earnings Update 18-26 Jiangsu Hengrui Med 18 Shenzhen Mindray 19 Wuxi Biologics 20-21 CSPC Pharmaceutical Group 21-22 Sino Biopharmaceutical 22-23 WuXi AppTec 23 Aier Eye Hospital Group 24 Yunnan Baiyao Group 25 Changchun High & New Tech 25 Innovent Biologics 26 Potential Risks 27-29 Citations 30 Definitions 30 kraneshares.com 2 [email protected] +1 (212) 933 0393 KraneShares MSCI All China Health Care Index ETF (Ticker: KURE) Standard Performance Cumulative % Data as of: 03/31/2020 Fund NAV Closing Price Index 1 Month -3.84% -5.34% -3.85% 3 Month 2.10% 3.03% 2.20% 6 Month 12.82% 13.26% 13.20% Since Inception -4.22% -4.26% -3.51% Avg Annualized % Data as of: 03/31/2020 Fund NAV Closing Price Index 1 Year 6.95% 7.58% 7.80% Since Inception -1.97% -1.99% -1.64% KURE’s gross expense ratio is 0.79%. Inception Date: 1/31/2018. The performance data quoted represents past performance. Past performance does not guarantee future results.
    [Show full text]
  • State-Run Industrial Enterprises in Fengtian, 1920-1931
    State Building, Capitalism, and Development: State-Run Industrial Enterprises in Fengtian, 1920-1931 A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Yu Jiang IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY Liping Wang, Ann Waltner October 2010 © Yu Jiang, 2010 Acknowledgements I am grateful that Department of History at University of Minnesota took a risk with me, somebody with no background in history. I also thank the department for providing a one-semester fellowship for my dissertation research. I am deeply indebted to Minnesota Population Center for hosting me in its IT team for many years – it allowed me, a former software engineer, to keep abreast of the latest developments in computer technology while indulging in historical studies. Thanks are especially due to Steve Ruggles (MPC director) and Pete Clark (IT director) for giving me this great opportunity. The source materials for this dissertation mostly come from Liaoning Provincial Archives, Liaoning Provincial Library, and Meihekou Archives. I thank these institutions for their help. Liaoning Shekeyuan offered both warm reception and administrative help right after I arrived in Shenyang. My archival research in Shenyang also benefited greatly from Chris Isett’s help. Su Chen from East Asian Library at University of Minnesota has been helpful numerous times in locating important documents. My committee members, Mark Anderson, Ted Farmer, M.J. Maynes, Ann Waltner, and Liping Wang provided valuable comments on the draft. M.J. and Ann’s thoughtful comments on a paper based on my dissertation helped improve my work.
    [Show full text]
  • A Study of the European Cosmetics Industry (2007)
    A Study of the European Cosmetics Industry Final Report Prepared for: European Commission, Directorate General for Enterprise and Industry Prepared by: Global Insight, Inc. October 2007 Contact Information Emilio Rossi Managing Director Business Planning Solutions, Europe Global Insight, (Italy) srl. Via S. Maria Segreta 6 20123 Milan +3902 8648 130 [email protected] Antonia Prlic Principal 1 Adelaide Street East Suite 2505, P.O. Box 198 Toronto, Ontario, M5C 2V9 Canada +1 416 682-7312 [email protected] Robert Hoffman Senior Consultant 1 Adelaide Street East Suite 2505, P.O. Box 198 Toronto, Ontario, M5C 2V9 Canada +1 416 682-7311 [email protected] 2 Table of Contents INTRODUCTION AND STRUCTURE OF THE STUDY........................................... 1 I. BROAD MARKET STUDY - MACRO/MICROECONOMIC CHARACTERISTICS...................................................................................................... 2 SUMMARY........................................................................................................................ 2 I.1 - MARKET SIZES ......................................................................................................... 3 I.2 - PER CAPITA COSMETICS CONSUMPTION................................................................... 5 I.3 - MARKET SEGMENTS ................................................................................................. 7 I.4 - MAIN PRODUCT TRENDS .......................................................................................
    [Show full text]